Zepbound vs Liraglutide: Long-Term Durability of Response

How the Two Drugs Work

Tirzepatide and liraglutide both activate GLP-1 receptors in the hypothalamus and gut, but that is where the similarity ends. Liraglutide is a single-agonist molecule that mimics native GLP-1 with about 97% amino-acid homology to human GLP-1. Tirzepatide adds a second action: it co-activates the glucose-dependent insulinotropic polypeptide (GIP) receptor with roughly equal potency. That dual signal produces greater satiety, faster gastric emptying suppression, and a more pronounced reduction in fat mass than GLP-1 signaling alone achieves.

GLP-1 Receptor Agonism: Shared Ground

Both drugs slow gastric emptying, reduce appetite, lower postprandial glucose, and cut caloric intake. A 2022 meta-analysis in Diabetes, Obesity and Metabolism confirmed that GLP-1 receptor agonists as a class reduce body weight by 3 to 8 kg over 6 to 12 months in people with obesity. Liraglutide sits at the lower end of that range in practice. [1]

The GIP Co-Agonism Advantage

GIP receptors are expressed in adipose tissue, and tirzepatide's activation of those receptors appears to shift the body's fat-storage set point downward more aggressively than GLP-1 alone can. Preclinical data from Jastreboff et al. (2022) in NEJM showed that the dual mechanism accounted for disproportionate fat-mass loss compared to lean-mass preservation, a profile that is clinically meaningful for metabolic health beyond the number on the scale. [2]

Half-Life and Dosing Frequency

Liraglutide has a half-life of approximately 13 hours, requiring daily injections. Tirzepatide has a half-life of roughly 5 days, allowing once-weekly dosing. Adherence data consistently show that once-weekly injectables have meaningfully higher 12-month persistence rates than daily injectables, which has its own indirect effect on long-term durability. [3]

SURMOUNT-1 vs SCALE Obesity: The Core Efficacy Numbers

No randomized head-to-head trial has yet directly compared tirzepatide against liraglutide for obesity. The comparison therefore rests on two landmark trials run in similar but not identical populations.

SURMOUNT-1 (Tirzepatide, NEJM 2022)

SURMOUNT-1 enrolled 2,539 adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity, without type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced a mean weight loss of 20.9% of body weight versus 3.1% for placebo. The 10 mg dose reached 19.5% and the 5 mg dose reached 15.0%. [2]

Critically, 57% of participants in the 15 mg group lost 20% or more of body weight. That benchmark is often described as "clinically significant" for metabolic outcomes by the Obesity Society's guidelines. [2]

SCALE Obesity (Liraglutide 3 mg, NEJM 2015)

SCALE Obesity enrolled 3,731 adults with similar BMI criteria. At 56 weeks, liraglutide 3 mg produced mean weight loss of 8.4% versus 2.4% for placebo (P<0.001). Roughly 33% of participants lost 10% or more of body weight. [4]

The 56-week endpoint is 16 weeks shorter than SURMOUNT-1's 72-week endpoint, which slightly favors liraglutide in a naive comparison. When SCALE data at 52 weeks is used (approximately 7.5% weight loss), the gap with tirzepatide's 72-week results remains large enough that it is not bridged by the time-point difference.

Putting the Numbers Side by Side

| Metric | Tirzepatide 15 mg (SURMOUNT-1) | Liraglutide 3 mg (SCALE Obesity) | |---|---|---| | Trial duration | 72 weeks | 56 weeks | | Mean weight loss | 20.9% | 8.4% | | Achieved ≥10% loss | ~88% | ~33% | | Achieved ≥20% loss | ~57% | ~11% | | Placebo comparison | P<0.001 | P<0.001 |

The difference in absolute weight loss is not a rounding error. It is clinically large by any standard metric.

Long-Term Durability: Does the Weight Stay Off?

Durability is the central clinical question for chronic obesity pharmacotherapy. Both agents require continued use to maintain results, and both show weight regain after discontinuation. The magnitude and speed of that regain differ.

Tirzepatide Durability: SURMOUNT-4 Evidence

The SURMOUNT-4 trial (published in JAMA 2023) followed participants who had lost weight on tirzepatide for 36 weeks, then randomized them to either continue tirzepatide or switch to placebo for an additional 52 weeks. Those who continued tirzepatide lost an additional 5.5% of body weight. Those switched to placebo regained 14.8% of body weight over those 52 weeks, recouping roughly two-thirds of their earlier loss. [5]

This finding is consistent with the "obesity as a chronic disease" framework: tirzepatide suppresses appetite and fat-storage signals only while it is present. Stopping the drug removes that suppression.

Liraglutide Durability: SCALE Maintenance and Extension Data

The SCALE Maintenance trial showed that adults who lost weight on a low-calorie diet and then started liraglutide maintained more weight loss than those on placebo over 56 weeks. However, a 160-week extension analysis of the original SCALE cohort found that weight loss plateaued around week 40 to 52 and was only partially maintained thereafter, with some regain occurring even in the treatment arm at longer follow-up. [4]

Real-world persistence data are also relevant. A 2021 retrospective cohort study in Obesity found that only 29% of patients prescribed liraglutide 3 mg remained on therapy at 12 months, compared to higher persistence rates seen with once-weekly agents. [3] Lower persistence translates directly to lower real-world durability regardless of what the trials show.

Weight Regain Kinetics After Stopping

Both drugs produce rapid regain after discontinuation, but the absolute amount of weight lost with tirzepatide means regain is larger in absolute kilograms. A patient who lost 25 kg on tirzepatide and then stopped may regain 15 to 17 kg within a year. A patient who lost 9 kg on liraglutide may regain 6 kg. The relative proportions are similar, but the absolute stakes differ. For patients who cannot stay on tirzepatide long-term, this means the clinical planning conversation must happen before the drug is prescribed, not after.

Side Effect Profiles and Tolerability Over Time

Gastrointestinal Adverse Events

Both drugs cause nausea, vomiting, diarrhea, and constipation, and both are more likely to cause these events during dose escalation. In SURMOUNT-1, nausea was reported in 31% of the tirzepatide 15 mg group and vomiting in 18%. In SCALE Obesity, nausea was reported in 39.3% of liraglutide participants and vomiting in 15.0%. [2,4]

The higher nausea rate with liraglutide in these trials likely reflects the daily peak-and-trough pharmacokinetics. Tirzepatide's once-weekly dosing produces a slower, flatter serum-concentration curve that may soften GI peaks.

Rare but Serious Risks

Both drugs carry class warnings for thyroid C-cell tumors based on rodent data, though the human relevance remains unproven. Liraglutide carries an FDA warning about pancreatitis risk. Tirzepatide's label includes the same caution. Neither drug is recommended in patients with a personal or family history of medullary thyroid carcinoma or MEN2. [6,7]

Gallbladder disease, including cholelithiasis, is more common with rapid weight loss regardless of agent. SURMOUNT-1 reported cholelithiasis in 0.6% of the tirzepatide arm vs. 0.2% placebo.

Long-Term Cardiovascular Safety

The SELECT trial (2023, NEJM) established that semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% in people with pre-existing cardiovascular disease and obesity. No equivalent cardiovascular outcomes trial has yet been completed for tirzepatide in obesity (the SURMOUNT-MMO trial is ongoing as of 2025) or for liraglutide at the 3 mg obesity dose. The LEADER trial did demonstrate cardiovascular benefit for liraglutide 1.8 mg in type 2 diabetes, but those results are not directly applicable to the 3 mg obesity population. [8]

Switching from Zepbound to Liraglutide: When Does It Make Sense?

The clinical case for switching from Zepbound to liraglutide is narrow. The situations where it could make sense fall into a short list.

Scenario 1: Cost and Insurance Coverage

Zepbound's list price is approximately $1,060 per month without insurance coverage. Generic liraglutide (emerging in the 1.8 mg diabetes dose) may eventually undercut that price, though the 3 mg obesity-indication generic market is still developing as of 2025. If a patient loses insurance coverage for Zepbound and cannot afford out-of-pocket costs, liraglutide or compounded options are sometimes the next practical step. Clinicians should review Eli Lilly's Zepbound Savings Card program before assuming the switch is inevitable.

Scenario 2: Tirzepatide Intolerance

Patients who cannot tolerate tirzepatide's GI side effects even at the 2.5 mg starting dose are rare, but they exist. Liraglutide's slower titration schedule (starting at 0.6 mg daily and increasing by 0.6 mg weekly to reach 3 mg) gives a granular dose-control option that tirzepatide's 2.5 mg starting floor does not provide. Some patients tolerate liraglutide's GI profile differently because of the pharmacokinetic differences noted above.

Scenario 3: Pregnancy Planning

Neither drug is approved during pregnancy. FDA labels for both agents recommend discontinuation prior to conception. If a patient on Zepbound is planning pregnancy, a switch to dietary management or other approved strategies is indicated rather than a switch to liraglutide, which carries the same label restriction. [6,7]

What to Expect When Switching

The HealthRX clinical team's framework for switching:

1. Complete the final tirzepatide dose.
2. Wait 1 to 2 weeks before beginning liraglutide, given tirzepatide's 5-day half-life. (Four half-lives equals approximately 20 days for full clearance; starting liraglutide after 7 to 14 days is a practical middle ground most providers use.)
3. Begin liraglutide at 0.6 mg daily and titrate per label.
4. Set realistic expectations: most patients will regain some weight during the transition and stabilize at a lower total weight loss than they achieved on tirzepatide.
5. Reassess at 12 weeks. If the patient has regained more than 5% of their lowest Zepbound weight, discuss escalation strategies or whether re-authorization for tirzepatide is feasible.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state: "Chronic pharmacologic therapy is generally required to maintain weight loss achieved with anti-obesity medications, and treatment should be individualized based on efficacy, tolerability, cost, and comorbidities." [9] That guidance applies equally to decisions about switching agents.

Real-World Considerations: Access, Cost, and Persistence

Generic Liraglutide and the Cost Equation

The FDA approved the first generic liraglutide (Victoza 1.8 mg equivalent) in 2024. The 3 mg obesity-dose generic market is following. Generic liraglutide at full 3 mg dosing could reduce monthly costs to the $200 to $400 range depending on pharmacy, which is a meaningful access shift for uninsured or underinsured patients. This is a genuine advantage liraglutide holds over tirzepatide, where no generic is on the near-term horizon.

Compounded Tirzepatide: A Separate Consideration

During the Zepbound shortage period (2023 to 2024), FDA enforcement discretion permitted compounding pharmacies to produce tirzepatide. As of 2025, the FDA has moved to restrict compounded tirzepatide as the shortage resolves. Patients relying on compounded tirzepatide as a cost-saving measure may face a forced switch, making liraglutide a transitional option worth understanding. [10]

Who Should Stay on Zepbound

Patients who have achieved 15% or more body weight loss on tirzepatide, have good tolerability, and have meaningful comorbidities (hypertension, prediabetes, PCOS, sleep apnea, NASH) have the most to lose from switching. The weight differential between the two drugs at 72 weeks is large enough that staying on tirzepatide, even with cost management strategies, is worth prioritizing before defaulting to liraglutide.

What the Evidence Does Not Yet Tell Us

No long-term comparative effectiveness trial beyond 3 years exists for either drug in obesity. SURMOUNT-1 extended follow-up data beyond 88 weeks has not been published as of mid-2025. Liraglutide's longest obesity-indication follow-up is approximately 3 years from the SCALE 160-week extension. Neither dataset answers whether metabolic benefits (glycemic control, cardiovascular risk reduction, liver fat reduction) are maintained at 5 or 10 years.

The ongoing SURMOUNT-MMO cardiovascular outcomes trial for tirzepatide should provide data on all-cause mortality and MACE in a high-risk obesity population. Results are anticipated around 2027. Until those data exist, cardiovascular prescribing decisions for tirzepatide in people without diabetes rely largely on extrapolation from the semaglutide SELECT trial. [11]